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HRQL studies in clinical trials, and how to evaluate the
validity of HRQL claims, for appropriate decision-mak-
ing.
METHOD: A guidance document and a checklist have
been designed following a literature search and using the
experience of the ERIQA group’s members, i.e., HRQL re-
searchers, pharmaceutical industry representatives, aca-
demic people, and reviewers for regulatory authorities.
RESULTS: The guidance document reviews the major is-
sues of HRQL assessment in clinical trials, and especially
practical considerations such as: selection of an HRQL
questionnaire (i.e., minimal properties required, validation
of translated versions); implementation of a HRQL assess-
ment (i.e., training of study personnel, mode of adminis-
tration, eligibility criteria, data collection, prevention of
missing data, respondent burden, multicenter trial); statis-
tical analysis (i.e., justification of the sample size, handling
of missing data, handling of multiple statistical tests), and
interpretation. For each issue, recommendations are made,
even when there is no definite answer (e.g., interpretation
of results). All the issues to be prespecified in the research
protocol are mentioned. The checklist summarizes all the
issues. It is intended to help both regulatory authority re-
viewers in performing their clinical trial reviews and spon-
sors and investigators in conducting a clinical trial with
HRQL data and writing the study report.
CONCLUSION: The final objective is to reach a large Eu-
ropean agreement upon this guidance document, to im-
prove the quality of HRQL studies and to convince Euro-
pean regulatory authorities of the usefulness and scientific
value of HRQL assessment.
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OBJECTIVES: To harmonize VAS values resulting from 11
studies in 6 countries (England, Finland, Germany, The
Netherlands, Spain and Sweden) using the EQ-5D valuation
questionnaire, developed by the EuroQol Group. The aim is
to make available a European EQ-5D value set and to gain
insight into the influences resulting from the prevailing dif-
ferences in methodology and sample characteristics.
METHODS: The database constructed for this research
project contains data on more than 110.000 health states
from 8370 respondents. Appropriate transformation was
applied to deal with ceiling and floor effects. Regression
models and a single value decomposition were applied to
explore the differences between the valuations in the 11
samples and the influences of background variables on
the VAS values of a subset of 18 health states. Multilevel
regression analysis on data of 49 health states was con-
ducted to take into account characteristics at the individ-
ual respondent level while testing the impact of health
state characteristics on the value set.
RESULTS: In general, the impact of the background vari-
ables such as age and experience of illness on the VAS val-
uations appeared to be modest. Differences in study meth-
odology have a higher impact on the VAS values but
differences in the health states themselves were found to be
the major determinant of VAS values.
CONCLUSIONS: When corrected for the influence of the
background variables, the VAS values from the 6 countries
showed a remarkable agreement. Differences can be attrib-
uted to differences in survey methodology and sample
characteristics rather than ‘cultural’ aspects. By using a
simple instrument, ie., the EQ-5D valuation questionnaire,
it seems that an internationally consistent EQ-5D value set
can be established.
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BACKGROUND: Health-related Quality of Life (HRQL)
of patients is increasingly being used as an endpoint in
multinational studies. In this era of international collabo-
ration, there is a critical need for improved interpretation
of HRQL studies and the confirmation of conceptual
equivalence of linguistically adapted HRQL instruments
used in multinational studies. In order to facilitate these
two objectives, Mapi Research Institute has launched the
development of IQOD.
OBJECTIVES: The primary objective of the IQOD proj-
ect is the development of an international database that
will contain HRQL, socio-demographic, and clinical data
from multinational HRQL studies. Once this database is
developed the following objectives can be realised: (1)
Development of reference values to facilitate interpreta-
tion of scale scores and making it possible to estimate the
relative burden of various medical and psychological con-
ditions across populations and across disease severities;
(2) Evaluation of the conceptual equivalence of linguisti-
cally adapted HRQL instruments used in multinational
studies; (3) Development of item banking.
METHODS: During the initial phase of this project, data
will be obtained from sponsors of international studies in
which linguistically valid HRQL questionnaires, provided
by Mapi Research Institute, were administered. There are
13 instruments included in the initial phase of this project.
The first step of the initial phase is the development of ref-
erence values for the Women’s Health Questionnaire
(WHQ) and the Minnesota Living with Heart Failure
Questionnaire (MLHF).
RESULTS: Results of the initial phase will be presented
upon completion of analysis.
